Additional file 6 of Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b

Additional file 6. Figure S1. Heatmap showing the differential expression (as log2-fold change) of significantly differentially expressed genes when comparing hAD tau seeded RCNs to unseeded RCNs (Seed - Control) and Anle138-treated hAD tau seeded RCNs to vehicle control hAD tau seeded RCNs (Anle + Seed - Seed) at DIV (days in vitro) 3. Figure S2. Heatmap showing the differential expression (as log2-fold change) of significantly differentially expressed genes when comparing hAD tau seeded RCNs to unseeded RCNs (Seed - Control) and Anle138-treated hAD tau seeded RCNs to vehicle control hAD tau seeded RCNs (Anle + Seed - Seed) at DIV (days in vitro) 7. Figure S3. Heatmap showing the differential expression (as log2-fold change) of significantly differentially expressed genes when comparing hAD tau seeded RCNs to unseeded RCNs (Seed - Control) and Anle138-treated hAD tau seeded RCNs to vehicle control hAD tau seeded RCNs (Anle + Seed - Seed) at DIV (days in vitro) 14. Figure S4. Most significantly enriched pathways at each time point in Anle138b-treated unseeded RCNs. Significance level of p = 0.05 is indicated as a red dashed line on the x-axis. Figure S5. Most enriched pathways at each time point in Anle138b-treated hAD Tau seeded RCNs. Significance level of p = 0.05 is indicated as a red dashed line on the x-axis. Table S1. DEGs overlapping with Open Targets (July 2020) Alzheimer’s Disease association list (bold) or Tauopathies association list (underlined) in each Anle138b perturbation experiment, as well as the overall overlap with AD + Tauopathies, and the corresponding Odd’s Ratio and p-value calculated with Fisher’s Exact Test. Table S2. Full list of overlapping pathways (FDR-adjusted p-value